When cancer strikes the young, infertility can result; now states act to help
Treatment for cancer and other serious conditions involves toxic chemotherapy drugs, radiation and surgery that can cause infertility in women and men.
Increasingly patients are seeking the advice of reproductive medicine clinicians and scientists to enable them to preserve their gametes and/or embryos. The reasons are either as a form of reproductive insurance, or more important, to preserve their fertility before undergoing gonadotoxic therapy, most commonly chemotherapy. It is a guideline of the American Society of Clinical Oncology that all health care providers caring for adult and pediatric patients with cancer should address the possibility of infertility as early as possible before treatment starts (1).
Vickie Sandilands, from Guisborough, North Yorkshire, was almost rendered infertile after undergoing chemotherapy to treat her breast cancer.
This article mainly opted advance nanotherapy methods, based on most recent studies. Result and conclusion- Nanotechnology provides new molecular contrasts agents and materials to enable earlier and more accurate initial diagnosis, as well as continual monitoring of patient while cancer treatment. This review concludes that nanotechnology as nanodrugs, nano carrier, nanoparticles in combination with radiological methods have a better future in cancer treatment. In this paper, several diagrammatic pathways presented the opted studies and proposed conclusion. PMID: 30426890 [PubMed - as supplied by publisher]
Authors: Cui W, Stern C, Hickey M, Goldblatt F, Anazodo A, Stevenson WS, Phillips KA Abstract Alkylating chemotherapy is often used to treat pre-menopausal women for various malignancies and autoimmune diseases. Chemotherapy-associated ovarian failure is a potential consequence of this treatment which can cause infertility, and increases the risk of other long term adverse health sequelae. Randomised trials, predominantly of women undergoing alkylating chemotherapy for breast cancer, have shown evidence for the efficacy of gonadotropin-releasing hormone agonists (GnRHa) in preventing chemotherapy-associated ovarian...
(Abstracted from Reprod Biomed Online 2018;36:711–718) A late marker for the resumption of follicle growth after chemotherapy is the final recovery of menstrual activity. This can be monitored by measuring concentrations of anti–müllerian hormone (AMH), which is a real-time indicator of both follicular depletion and renewal of growth.
AbstractChemotherapy-induced gonadal dysfunction resulting in transient or persistent infertility depends on the type of drugs and cumulative dose, and it is an important long-term complication, especially for adolescent and young adult (AYA) cancer patients. Due to its importance, a clinical practice guideline for fertility preservation in childhood and AYA cancer patients was published by the Japan Society of Clinical Oncology (JSCO) in 2017. Although the precise mechanisms remain unclear, several studies reported that the cancer itself, not the cancer treatment, adversely affected semen quality. It is reported that that...
(Natural News) Conventional treatments for cancer, such as chemotherapy and radiation, are known for targeting even healthy cells. The damage induced on healthy cells by non-selective targeting these cancer treatments lead to side effects like diarrhea, anemia, infertility, mood changes, and weight loss. To avoid these side effects, people are now turning to traditional medicine...
Conclusion: The patients of SLCT can present with hormonal magnification and manifest high AFP, CA125, and T levels. SLCT is characterized by a solid or mixed solid-cystic mass on CT/MR scans, and shows marked or moderated heterogeneous and constantly enhancement upon postcontrast study. The clinical characteristics and imaging findings are features and appropriated imaging should be performed whenever an SLCT is suspected.
We report a case of a 42-year-old woman with a history of bilateral ductal carcinoma of the breast who underwent radical mastectomy with chemotherapy and radiotherapy was anxious to conceive. In vitro fertilization was performed with donor oocyte; the patient became pregnant and delivered a full term baby with no congenital anomalies. As very few have a background for providing guidance and treatment in this setting, this report highlights the possibility of improving the quality of reproductive life of young survivors by various assisted reproductive techniques, the importance of fertility preservation and a multidisciplinary team approach.
This article discusses these exciting new developments in the treatment of advanced-stage Hodgkin lymphoma.